No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Headquartered in New Delhi, India, Mankind Pharma Limited is a prominent developer, manufacturer, and marketer of pharmaceutical formulations and consumer healthcare products. The company's primary focus is on the Indian market, though it also boasts an international reach. Its extensive pharmaceutical portfolio addresses a broad spectrum of acute and chronic therapeutic areas, encompassing anti-infectives, cardiovascular and gastrointestinal health, anti-diabetic treatments, dermatology, pain management, neurological and CNS disorders, vitamin/mineral/nutrient supplements, and respiratory conditions. Complementing its pharmaceutical offerings, Mankind Pharma provides a variety of consumer healthcare essentials, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, dietary supplements, and anti-acne preparations. These popular products are primarily marketed under recognized brand names such as Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Beyond its core business, the company is involved in the trading and exporting of pharmaceutical and healthcare items, manufacturing packing materials, Ayurvedic products, bulk drugs, and consumer goods. Its diverse operations further extend into real estate, leasing, hospitality, and IT services. Mankind Pharma Limited was established in 1986.
www.mankindpharma.comNo one on the platform currently holds MANKIND.BO.
No tracked institution reports a position in MANKIND.BO as of their last filing.
No one on the platform has traded MANKIND.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.2% | 15.4% | — | — | — | |
| Rev. Growth % | 17.0% | 18.1% | ||||
| Profit Margin % | 13.4% | 16.3% | ||||
| Free Cash Flow Margin % | 13.2% | 7.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $160.6B | +12.5% | $57.15 | $51.42–$64.64 | — | 17 |
| 2028 | $179.1B | +11.6% | $70.43 | $63.07–$79.11 | — | 17 |
| 2029 | $199.1B | +11.1% | $83.77 | $74.46–$97.82 | — | 9 |
| 2030 | $230.0B | +15.5% | $105.56 | $102.92–$110.09 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $13.31 | $13.80 | +3.7% |
| 2026-05-19 | $10.15 | $14.00 | +37.9% |
| 2026-02-03 | $12.04 | $12.10 | +0.5% |
| 2025-11-06 | $12.71 | $12.40 | -2.4% |
| 2025-07-31 | $10.92 | $10.70 | -2.0% |
| 2025-05-21 | $9.87 | $9.15 | -7.3% |
| 2025-01-23 | $11.36 | $9.45 | -16.8% |
| 2024-11-05 | $14.55 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MANKIND.BOMankind Pharma Limited | $2277.00 | +1.38% | $940.3B | — |
| ALKEM.BOAlkem Laboratories Limited | $5089.50 | -0.41% | $607.6B | — |
| ALKEM.NSAlkem Laboratories Limited | $5089.50 | -0.94% | $608.5B | — |
| DRREDDY.BODr. Reddy's Laboratories Limited | $1161.00 | +1.77% | $975.5B | — |
| DRREDDY.NSDr. Reddy's Laboratories Limited |
| $16.28 |
| +11.9% |
| $1165.50 |
| +1.97% |
| $970.9B |
| — |
| LUPIN.BOLupin Limited | $2096.00 | +1.01% | $955.8B | — |
| LUPIN.NSLupin Limited | $2095.00 | +0.83% | $957.9B | — |
Source: Financial Modeling Prep · peers by sector/industry